Variant allele frequency enrichment analysis in vitro reveals sonic hedgehog pathway to impede sustained temozolomide response in GBM.

PubWeight™: 0.79‹?›

🔗 View Article (PMC 4300501)

Published in Sci Rep on January 21, 2015

Authors

Nidhan K Biswas1, Vikas Chandra1, Neeta Sarkar-Roy1, Tapojyoti Das1, Rabindra N Bhattacharya2, Laxmi N Tripathy3, Sunandan K Basu3, Shantanu Kumar1, Subrata Das1, Ankita Chatterjee1, Ankur Mukherjee1, Pryiadarshi Basu1, Arindam Maitra1, Ansuman Chattopadhyay4, Analabha Basu1, Surajit Dhara1

Author Affiliations

1: National Institute of Biomedical Genomics, Kalyani, West Bengal 741251, India.
2: AMRI Hospitals, JC-16 Salt Lake City, Kolkata 700098, India.
3: Medica Superspeciality Hospital, 127 Mukundapur, Kolkata 700099, India.
4: University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA 15261, USA.

Articles cited by this

A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55

MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65

The DNA damage response: making it safe to play with knives. Mol Cell (2010) 16.13

Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

DNA damage, aging, and cancer. N Engl J Med (2009) 7.56

Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell (2009) 7.09

Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82

Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (2014) 6.09

Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12

DNA damage-induced cell death by apoptosis. Trends Mol Med (2006) 4.67

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J (2008) 2.95

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer (1992) 2.91

The implications of clonal genome evolution for cancer medicine. N Engl J Med (2013) 2.78

Non-genetic heterogeneity--a mutation-independent driving force for the somatic evolution of tumours. Nat Rev Genet (2009) 2.69

Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol (2012) 2.56

Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med (2013) 2.55

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry (1994) 2.27

The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature (2014) 2.21

Spatial dynamics of chromosome translocations in living cells. Science (2013) 1.95

Fused has evolved divergent roles in vertebrate Hedgehog signalling and motile ciliogenesis. Nature (2009) 1.69

Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nat Commun (2013) 1.62

Gli regulation by the opposing activities of fused and suppressor of fused. Nat Cell Biol (2000) 1.41

Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol (2011) 1.31

Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med (2013) 1.19

U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res (2013) 1.06

Tissue morphogenesis and vascular stability require the Frem2 protein, product of the mouse myelencephalic blebs gene. Proc Natl Acad Sci U S A (2005) 1.03

Metabolism of lysine in alpha-aminoadipic semialdehyde dehydrogenase-deficient fibroblasts: evidence for an alternative pathway of pipecolic acid formation. FEBS Lett (2010) 1.03

Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. Cancer Lett (2010) 0.98

Sustained activation of DNA damage response in irradiated apoptosis-resistant cells induces reversible senescence associated with mTOR downregulation and expression of stem cell markers. Cell Cycle (2014) 0.87

A RSK(y) relationship with promiscuous PKA. Sci STKE (2006) 0.82

DNA-dependent protein kinase and its inhibition in support of radiotherapy. Int J Radiat Biol (2013) 0.81

Expression of an isoform of the novel signal transduction protein ST5 is linked to cell morphology. Oncogene (1999) 0.80